Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

This article was originally published in The Pink Sheet Daily

Executive Summary

In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.

You may also be interested in...



Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.

What's Next For Bristol's Opdivo/Yervoy Combination

Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.

AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC

Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel